ROLE_ANONYMOUS
Updated on 01/03/2019
About MSD Immunology
MSD immunology is proud to be at the forefront of patient care and remains committed to help patients overcome the burden of debilitating chronic diseases now and in the future.
MSD has two widely used anti-TNF (Tumour Necrosis Factor) products with licences across three therapeutic areas: Gastroenterology, Rheumatology and Dermatology.1,2
made history as the first anti-TNF to enter the market1
REMICADE has gained 8 licensed indications across Gastroenterology (Crohns disease and Ulcerative Colitis), Rheumatology (rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis) and Dermatology (psoriasis).1 REMICADE has helped to support the lives of over 2.6 million patients worldwide.3
has four licenced indications in Rheumatology:2
A self-injectable biologic treatment SIMPONI (golimumab) was developed to fit with patient needs and lifestyle, whilst continuing to improve functionality and disease outcomes. It is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing from day one, licensed for Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis and a 4-weekly dosing schedule for Ulcerative Colitis.2
To learn more and to visit the product pages please click below.
References
- REMICADE 100 mg powder for concentrate for solution for infusion Summary of Product Characteristics.
- SIMPONI 50 mg and SIMPONI 100 mg Summary of Product Characteristics.
- MSD data on file PSUR Oct 2016.
Supporting documentation
REMICADE
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
SIMPONI 50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for pre-filled syringe | Patient Information Leaflet for pre-filled pen
SIMPONI 100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for pre-filled pen
GB-GOL-00111 | Date of Preparation: March 2019